Bacteriophage Therapy

Global Bacteriophage Therapy Market to Reach US$1.5 Billion by 2030

The global market for Bacteriophage Therapy estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. E. Coli, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$364.7 Million by the end of the analysis period. Growth in the Staphylococcus Aureus segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$351.1 Million While China is Forecast to Grow at 4.5% CAGR

The Bacteriophage Therapy market in the U.S. is estimated at US$351.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$281.7 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Bacteriophage Therapy Market – Key Trends & Drivers Summarized

Why Is Bacteriophage Therapy Re-Emerging as a Promising Alternative Amid the Global Antimicrobial Resistance Crisis?
Bacteriophage therapy—using viruses that selectively infect and destroy bacterial cells—is gaining renewed momentum as a viable alternative to traditional antibiotics, especially in the fight against multidrug-resistant (MDR) infections. As antimicrobial resistance (AMR) escalates into a global public health emergency, with conventional antibiotics becoming less effective against evolving pathogens, phage therapy offers a highly targeted approach that bypasses the collateral damage to the host microbiome and minimizes the risk of resistance proliferation.

Phages can be custom-tailored to specific bacterial strains, making them especially valuable for treating chronic, biofilm-associated, or hospital-acquired infections such as Pseudomonas aeruginosa, Acinetobacter baumannii, and MRSA. Unlike broad-spectrum antibiotics, phage therapy preserves beneficial bacteria and can be used in combination with antibiotics for synergistic effects. The resurgence of interest is also being catalyzed by landmark compassionate use cases, regulatory openness to personalized therapies, and the growing urgency to expand the infectious disease treatment arsenal beyond chemically synthesized drugs.

How Are Genomic Tools, Synthetic Biology, and Regulatory Frameworks Advancing Phage Therapy Development?
Cutting-edge tools in genomics and synthetic biology are revolutionizing the development and precision of phage therapeutics. Whole-genome sequencing allows rapid identification of lytic phages and eliminates candidates with undesirable traits such as lysogeny or toxin genes. CRISPR and other gene editing techniques are being used to engineer phages with enhanced infectivity, broader host ranges, and resistance-mitigating capabilities. These bioengineered phages can target biofilm-producing pathogens, modulate host immune responses, and deliver therapeutic payloads in complex infection sites.

Regulatory interest in flexible approval pathways—especially for personalized and compassionate use therapies—is accelerating clinical adoption. Agencies like the U.S. FDA and European Medicines Agency (EMA) are supporting investigational new drug (IND) applications and encouraging innovation through orphan drug designations and adaptive trial designs. Additionally, the establishment of phage banks and production platforms capable of rapid isolation and GMP-grade manufacturing is enabling scalable, standardized development models—bridging the gap between experimental treatment and broader commercialization.

Where Is Demand for Bacteriophage Therapy Growing and Which Applications Are Leading Clinical Focus?
Demand for bacteriophage therapy is growing globally, with active research hubs in the United States, Europe (notably Belgium, Poland, and France), Russia, and increasingly in Asia-Pacific countries such as India and South Korea. Clinical trials are expanding across therapeutic areas such as cystic fibrosis-associated infections, diabetic wound care, gastrointestinal disorders, and urinary tract infections (UTIs), where antibiotic failure rates are particularly high. Hospitals and academic centers are piloting phage therapy in ICU settings, burn units, and immunocompromised patient care as part of salvage treatments.

Pharmaceutical and biotech firms are also targeting phage therapy for applications in agriculture and veterinary medicine, where overuse of antibiotics in livestock has accelerated resistance concerns. In parallel, microbiome restoration and targeted gut decolonization are emerging as novel frontiers for phage-based therapeutics. The food safety and sanitation sectors are exploring phage preparations as natural antibacterials to control pathogens like Listeria and Salmonella—opening non-clinical avenues for phage adoption.

What Is Fueling the Global Growth of the Bacteriophage Therapy Market?
The global growth of the bacteriophage therapy market is fueled by the urgent demand for alternative antimicrobials, advances in precision biology, and expanding public and private investment in AMR solutions. Supportive regulatory sentiment, rising venture capital in phage biotech startups, and international collaborations—such as the Phage Directory and Global Phage Initiative—are building a framework for innovation, clinical validation, and eventual market scalability. High-profile case studies demonstrating phage efficacy where antibiotics failed are further reinforcing public and medical interest.

Challenges such as narrow host range, regulatory complexity, and limited large-scale trial data remain, but are being actively addressed through personalized phage cocktails, bioinformatics-driven matching algorithms, and GMP-compliant phage manufacturing ecosystems. As AMR continues to threaten modern healthcare foundations, a pivotal question defines the path ahead: Can bacteriophage therapy evolve from last-resort intervention to front-line precision antimicrobial—integrating into clinical guidelines, manufacturing pipelines, and health system protocols as a next-generation solution to the antibiotic resistance crisis?

SCOPE OF STUDY:

The report analyzes the Bacteriophage Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Targeted Bacteria (E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella, Other Targeted Bacterias); Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications); Administration Route (Oral, Topical, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Adaptive Phage Therapeutics
• Armata Pharmaceuticals, Inc.
• BiomX Ltd.
• Biochimpharm
• ContraFect Corporation
• Eligo Bioscience
• Eliava Biopreparations Ltd.
• Enbiotix, Inc.
• Fixed-Phage Ltd.
• InnoPhage Ltd.
• Intralytix, Inc.
• iNtODEWorld, Inc.
• Locus Biosciences, Inc.
• Micreos BV
• Microgen
• Nextbiotics
• OPTIPHARM Co., Ltd.
• PhagePro, Inc.
• Phagelux, Inc.
• Pherecydes Pharma

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.